sublocade
sublocade: developed by 1 company · 3 clinical trials tracked.
sublocade evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could sublocade → INDV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) Moderate to Severe Opioid Use Disorder; Opioid-use Disorder;… | Phase 2 |
Clinical Trials (3)
An Open-label, Multicentre Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Repeated Doses of INDV-6001 in Adults With Moderate to Severe Opioid Use Disorder
Primary endpoint: Steady-state area under the plasma concentration-time curve over the dosing interval (AUCtau) of buprenorphine following INDV-6001 injection in the abdomen
An Open-label, Treatment Extension Study for the Rapid Initiation of Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE™)
Primary endpoint: Treatment Emergent Adverse Event (TEAE) Occurrence
An Open-label, Rapid Initiation Study for Extended-Release Buprenorphine Subcutaneous Injection (SUBLOCADE)
Primary endpoint: Participants Who Experienced Any Precipitated Withdrawal Within One Hour After SUBLOCADE Administration
Frequently asked questions
Who is developing sublocade?
sublocade is being developed by Indivior Pharmaceuticals, Inc..
How many clinical trials involve sublocade?
BioSniper tracks 3 clinical trials involving sublocade.